1. Home
  2. DSS vs ONCO Comparison

DSS vs ONCO Comparison

Compare DSS & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DSS
  • ONCO
  • Stock Information
  • Founded
  • DSS 1984
  • ONCO 2018
  • Country
  • DSS United States
  • ONCO United States
  • Employees
  • DSS N/A
  • ONCO N/A
  • Industry
  • DSS Containers/Packaging
  • ONCO Biotechnology: Pharmaceutical Preparations
  • Sector
  • DSS Consumer Discretionary
  • ONCO Health Care
  • Exchange
  • DSS Nasdaq
  • ONCO Nasdaq
  • Market Cap
  • DSS 7.3M
  • ONCO 9.4M
  • IPO Year
  • DSS N/A
  • ONCO 2022
  • Fundamental
  • Price
  • DSS $0.95
  • ONCO $0.54
  • Analyst Decision
  • DSS
  • ONCO
  • Analyst Count
  • DSS 0
  • ONCO 0
  • Target Price
  • DSS N/A
  • ONCO N/A
  • AVG Volume (30 Days)
  • DSS 18.3K
  • ONCO 9.9M
  • Earning Date
  • DSS 03-26-2025
  • ONCO 04-10-2025
  • Dividend Yield
  • DSS N/A
  • ONCO N/A
  • EPS Growth
  • DSS N/A
  • ONCO N/A
  • EPS
  • DSS N/A
  • ONCO N/A
  • Revenue
  • DSS $25,019,000.00
  • ONCO $1,870,605.00
  • Revenue This Year
  • DSS N/A
  • ONCO N/A
  • Revenue Next Year
  • DSS N/A
  • ONCO N/A
  • P/E Ratio
  • DSS N/A
  • ONCO N/A
  • Revenue Growth
  • DSS N/A
  • ONCO N/A
  • 52 Week Low
  • DSS $0.77
  • ONCO $0.32
  • 52 Week High
  • DSS $2.30
  • ONCO $21.40
  • Technical
  • Relative Strength Index (RSI)
  • DSS 56.49
  • ONCO 43.36
  • Support Level
  • DSS $0.81
  • ONCO $0.53
  • Resistance Level
  • DSS $0.97
  • ONCO $0.70
  • Average True Range (ATR)
  • DSS 0.07
  • ONCO 0.06
  • MACD
  • DSS 0.01
  • ONCO 0.00
  • Stochastic Oscillator
  • DSS 81.82
  • ONCO 15.40

About DSS DSS Inc.

DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia.

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

Share on Social Networks: